Company Profile

CIPLA LTD.

NSE : CIPLABSE : 500087ISIN CODE : INE059A01026Industry : Pharmaceuticals & DrugsHouse : Cipla
BSE786.55-22.55 (-2.79 % )
PREV CLOSE (Rs.) 809.10
OPEN PRICE (Rs.) 806.70
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 395970
TODAY'S LOW / HIGH (Rs.)780.20 820.35
52 WK LOW / HIGH (Rs.)356.75 878.55
NSE787.05 -22.1 (-2.73 % )
PREV CLOSE(Rs.) 809.15
OPEN PRICE (Rs.) 805.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 787.05 (4643 )
VOLUME 7549015
TODAY'S LOW / HIGH(Rs.) 780.00 820.00
52 WK LOW / HIGH (Rs.)355.3 878.9

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.03
Dividend Yield(%) 0.51
TTM EPS (Rs.) 32.98
P/E Ratio 23.85
Book Value (Rs.) 233.61
Face Value (Rs.) 2
MCap (Rs. in Mn) 634321.46
Price/Earning (TTM) 19.58
Price/Sales (TTM) 4.71
Price/Book (MRQ) 3.37
PAT Margin (%) 17.10
ROCE (%) 18.08
Incorporation Year : 1935

Management Info :

Y K Hamied - Chairman Umang Vohra - Managing Director

Registered Office :

Address : Cipla House,Peninsula Business Park,Ganpatrao Kadam Marg, Lower Parel,
Mumbai,
Maharashtra-400013

Phone : 022-24826000 / 022-24826951

Website : www.cipla.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg, MCX
NEWS More
02Feb02-02-2021$Cipla gains on reporting 2-fold jump in Q3 consolidated net profit Cipla gains on reporting 2-f

Cipla is currently trading at Rs. 807.40, up by 1.85 points or 0.23% from its previous closing of Rs. 805.55 on the BSE.

The scrip opened at Rs. 810.00 and has touched a high and low of Rs. 817.20 and Rs. 805.45 respectively. So far 151227 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 869.65 on 12-Jan-2021 and a 52 week low of Rs. 356.75 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 855.95 and Rs. 785.55 respectively. The current market cap of the company is Rs. 65186.20 crore.

The promoters holding in the company stood at 36.70%, while Institutions and Non-Institutions held 40.05% and 23.25% respectively.

Cipla has reported 2-fold jumps in its net profit at Rs 698.93 crore for the quarter ended December 31, 2020 as compared to net profit at Rs 282.22 crore for the same quarter in the previous year. Total income of the company increased by 27.61% at Rs 3827.67 crore for Q3FY21 as compared Rs 2999.48 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported 2-fold jump in its net profit attributed to the shareholders at Rs 748.15 crore for the quarter ended December 31, 2020 as compared to net profit at Rs 351.03 crore for the same quarter in the previous year. Total income of the company increased by 18.29% at Rs 5255.63 crore for Q3FY21 as compared Rs 4443.13 crore for the corresponding quarter previous year.

Cipla is currently trading at Rs. 807.40, up by 1.85 points or..
01Feb02-01-2021$Cipla reports 2-fold jump in Q3 consolidated net profit Cipla reports 2-fold jump in

Cipla has reported results for third quarter ended December 31, 2020.

The company has reported 2-fold jumps in its net profit at Rs 698.93 crore for the quarter under review as compared to net profit at Rs 282.22 crore for the same quarter in the previous year. Total income of the company increased by 27.61% at Rs 3827.67 crore for Q3FY21 as compared Rs 2999.48 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported 2-fold jump in its net profit attributed to the shareholders at Rs 748.15 crore for the quarter under review as compared to net profit at Rs 351.03 crore for the same quarter in the previous year. Total income of the company increased by 18.29% at Rs 5255.63 crore for Q3FY21 as compared Rs 4443.13 crore for the corresponding quarter previous year.

Cipla has reported results for third quarter ended December 31,..
11Jan01-11-2021$Cipla recalling over 5.8 lakh packets of gastric ulcer treatment drug in US Cipla recalling over 5.8 lak

Cipla is recalling over 5.8 lakh packets of a drug for the reduction in the occurrence of gastric ulcers from the US market. The drug major is recalling esomeprazole magnesium for delayed-release oral suspension in unit dose packets in strengths 10 mg, 20 mg and 40 mg in the US market.

The drug firm has manufactured the affected lot at its Kurkumbh facility in Maharashtra and then supplied to its New Jersey-based subsidiary. The USFDA cited ‘cross-contamination with other products’ as the reason for the company recalling the product.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla is recalling over 5.8 lakh packets of a drug for the redu..
11Jan01-11-2021$Cipla trades higher on the bourses Cipla trades higher on the b

Cipla is currently trading at Rs. 847.55, up by 9.20 points or 1.10% from its previous closing of Rs. 838.35 on the BSE.

The scrip opened at Rs. 839.50 and has touched a high and low of Rs. 852.00 and Rs. 832.60 respectively. So far 120795 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 846.00 on 08-Jan-2021 and a 52 week low of Rs. 356.75 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 846.00 and Rs. 815.35 respectively. The current market cap of the company is Rs. 68302.73 crore.

The promoters holding in the company stood at 36.70%, while Institutions and Non-Institutions held 39.82% and 23.48% respectively.

Cipla is recalling over 5.8 lakh packets of a drug for the reduction in the occurrence of gastric ulcers from the US market. The drug major is recalling esomeprazole magnesium for delayed-release oral suspension in unit dose packets in strengths 10 mg, 20 mg and 40 mg in the US market.

The drug firm has manufactured the affected lot at its Kurkumbh facility in Maharashtra and then supplied to its New Jersey-based subsidiary. The USFDA cited ‘cross-contamination with other products’ as the reason for the company recalling the product.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla is currently trading at Rs. 847.55, up by 9.20 points or..
06Jan01-06-2021$ Board Meeting Intimation for Notice Of The Board Meeting Board Meeting Intimation fo
CIPLA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2021 ,inter alia, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended 31st December, 2020. In terms of the Company's Code of Conduct for Prevention of Insider Trading, the 'Trading Window' for dealing in the securities of the Company has been closed from 1st January, 2021 till 31st January, 2021 (both days inclusive).
CIPLA LTD.has informed BSE that the meeting of the Board of Dir..
Financials More
Rs. in Millions
QTR Dec 20 ANNUAL 20
Net Profit6989.323181.7
Gross Profit 9473.7 29643.1
Operating Profit 10922.736001.4
Net Sales 37315.5126591.5
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Sanofi India (BSE)
 8268.85 (1.40%)
M.Cap ( in Cr)
19043.68
Abbott India (BSE)
 14396.65 (0.34%)
M.Cap ( in Cr)
30591.88
Orchid Pharma (BSE)
 885.15 (5.00%)
M.Cap ( in Cr)
3612.86
Alembic Pharma (BSE)
 919.15 (2.38%)
M.Cap ( in Cr)
18067.10
Natural Capsules (BSE)
 117.40 (19.98%)
M.Cap ( in Cr)
73.17
Shareholding Pattern More
PROMOTERS 36.7 %
NON-INSTITUTION 23.25 %
FI/BANKS/INSURANCE 2.08 %
MUTUAL FUNDS/UTI 15.58 %
FII 0.01 %
GOVERNMENT 0 %
F & O Quotes